MedPath

Intensive management of infection in high risk leukemia

Not Applicable
Conditions
Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]Health Condition 2: C920- Acute myeloblastic leukemia
Registration Number
CTRI/2019/11/022080
Lead Sponsor
Jawaharlal Institute of Postgraduate Medical Education and Research
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

i.AML on intensive induction chemotherapy.

ii.Relapsed acute leukemia on salvage chemotherapy.

Exclusion Criteria

1.Patient not willing to give consent

2.Acute promyelocytic leukemia

3.Patient with documented infection (clinically/microbiologicaly) at the start of Induction/ salvage chemotherapy.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To assess the effect of sepsis bundle based protocol on 30 day mortality among patients with very high risk febrile neutropeniaTimepoint: The data will be collected for the first 30 days of intensive induction treatment
Secondary Outcome Measures
NameTimeMethod
To study the clinical outcomes (change in MSOFA score at 48 hours ,occurence of septic shock, organ dysfunction, requirement of ventilatory support) in very high risk febrile neutropenia patients managed with sepsis bundle based protocol. <br/ ><br>2.To identify the association of baseline clinical factors, laboratory parameters, profile of infections and pattern of sepsis bundle compliance with 30 day mortality and other clinical outcomes in very high risk febrile neutropenia patients. <br/ ><br>Timepoint: 30days
© Copyright 2025. All Rights Reserved by MedPath